Author

Z. Makhado

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2

Frequent Co-Authors

F. Ayres· 3 shared L. Morris· 3 shared P. Kgagudi· 3 shared P. Moore· 2 shared T. Moyo-Gwete· 2 shared A. Iranzadeh· 1 shared B. E. Lambson· 1 shared B. Lambson· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

F. Ayres

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms

T. Moyo-Gwete, C. Scheepers, Z. Makhado, P. Kgagudi, N. B. Mzindle, R. Ziki, S. Madzorera, N. P. Manamela, F. Ayres, B. E. Lambson, S. I. Richardson, L. Morris, P. L. Moore

This study investigates how different isotypes of the same HIV-neutralizing antibody achieve enhanced neutralization potency through distinct mechanisms involving hinge and CH1 regions.

bioRxiv · Aug 17, 2022 · PreprintImmunology

Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant.

P. Moore, T. Moyo, T. Hermanus, P. Kgagudi, F. Ayres, Z. Makhado, J. Sadoff, M. Le Gars, G. van Roey, C. Crowther, N. Garrett, L.-G. Bekker, L. Morris, H. Schuitemaker, G. Gray

The study assesses neutralizing antibody activity against 501Y.V2 variant post-Ad26.COV2.S vaccination, finding reduced neutralization but potential protection via other immune mechanisms.

bioRxiv · Jun 9, 2021 · PreprintImmunology

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies

T. Moyo-Gwete, M. Madzivhandila, Z. Makhado, F. Ayres, D. Mhlanga, B. Oosthuysen, B. Lambson, P. Kgagudi, H. Tegally, A. Iranzadeh, D. Doolabh, L. Tyers, L. Chinhoyi, M. Mennen, S. Skelem, , P. Moore

This study examines antibody responses to the SARS-CoV-2 501Y.V2 variant in patients hospitalized in early 2021, finding robust cross-reactivity against earlier variants and the 501Y.V3 variant.

bioRxiv · Mar 6, 2021 · PreprintImmunology